Figure 5. mir-99b targets MAP2K1 in AML-12 cells. (A) The binding analysis between MAP2K1 and miR-99b. (B, C) The dual luciferase reporter assays of MAP2K1 were conducted in (B) AML-12 cells and (C) primary hepatocytes treated with control mimic or miR-99b mimic. (D) The Western blot analysis of MAP2K1 was carried out in the AML-12 cells treated with control mimic or miR-99b mimic. *P < 0.05.